One bill to be considered by the committee, filed by Democratic House Majority Leader Ronald Mariano, is meant to promote transparency in the pharmaceutical industry by getting drug companies in front of the Health Policy Commission to evaluate how they arrive at their prices.

“Drugs are a huge contributor to health care costs, and it’s becoming, as many other parts of health care, more and more of a crisis in terms of people’s ability to pay for their health care,” state Sen.“We need to start with much more transparency around drug pricing, the true cost of bringing drugs to market and how those true costs relate to the cost of our drugs.”

Friedman, a Democrat, chairs the Joint Committee on Health Care Financing, which will hold its first hearing April 11 to examine over 20 bills meant to address pharmaceutical access, costs and transparency.[Review ICO Agate]<“Prescription drugs are sometimes a huge make-or-break deal.One of the top spenders, Pharmaceutical Research and Manufacturers of America (PhRMA), paid lobbyists more than $292,836 in 2018, state records show.

“Simply put, dangerous price controls will not address the challenges patients face affording their medicines and could limit a patient’s access to the treatments and medicines they need,” PhRMA spokeswoman Tiffany Haverly said.[Facebook Attack Is Video Exploring Live After Restrictions For Christchurch]

Haverly added that the association is “committed to working with local leaders to find solutions that help combat the opioid crisis.”

Prescription drug spending has experienced the highest growth rate among major service categories in recent years, climbing 5 percent to $9.7 billion in 2017, according to the Center for Health Information and Analysis’ annual report.Health care spending overall in Massachusetts reached $61.1 billion in 2017, a 1.6 percent increase from the year prior, according to the report.

Pharmaceutical companies are spending millions on lobbying as lawmakers consider a bundle of bills that address rising prescription drug costs and transparency.[IoTBlock Review ICO]

Pharmaceutical companies spent more than $4 million lobbying on Beacon Hill in 2018, according to a Herald analysis of state data.

“This is a huge cost-driver of health care costs,” Jones said.Some people, frankly, have to decide whether they get their prescriptions or give something else up that’s a necessity.”

.Cindy Friedman told the Herald.[Bitcoin Announcing Coinbase Support On Wallet BTC]

“Someone has to look at this with greater resources than we have in the Legislature and more knowledge than we have in the Legislature,” Mariano said. “The hope is that when these people have to come in and explain how they arrived at a cost, we can begin to see where there are opportunities to decrease costs.”

Related Articles

    Five Verity health clinics to remain open after sale, new owners say Judge blocks Medicaid work requirements in Kentucky, Arkansas Editorial: Back Alameda wellness center; reject park subterfuge Federal judge strikes down 20-week abortion ban in NC To the delight of Democrats, Trump pivots to health care
Republican House Minority Leader Brad Jones filed two bills that will be reviewed at the hearing as well, one relative to prescription drug pricing transparency and the other to establish a commission to review contracts between pharmaceutical benefit managers and MassHealth.
Source: https://www.mercurynews.com/2019/03/30/pharma-firms-spend-millions-lobbying-as-mass-lawmakers-consider-price-controls/

No comments yet. Be first to leave one!